CGNH OTC

CardioGenics Holdings Inc. focuses on the creation and global distribution of diagnostic testing solutions within the in vitro diagnostics (IVD) sector, serving markets across the United States, Canada, Europe, and other international regions. A key offering is the QL Care Analyzer, an automated, self-contained, and portable point-of-care (POC) immunoassay device. This analyzer utilizes a unique, patented self-metering cartridge to perform immunoassay evaluations directly at the point of care. The company also provides a range of immunoassay panels specifically engineered to detect cardiac biomarkers in blood, which is vital for identifying heart attacks. Additionally, CardioGenics supplies paramagnetic beads, serving as crucial solid supports in heterogeneous immunoassay procedures for both clinical and research institutions. Established in 1997, the company was initially known as Jag Media Holdings, Inc. before officially changing its name to CardioGenics Holdings Inc. in 2009. Its corporate headquarters are situated in Mississauga, Canada.